How it works
Three compounds firing on different timescales — no overlap, no redundancy
Nasal caffeine bypasses gastric absorption entirely — working levels in 2–5 minutes versus 45+ minutes oral. Blocks adenosine A1/A2A receptors, increasing dopamine and norepinephrine signaling. The fastest-acting compound in the formula.
CRL-40,941 — 3–4× more potent than adrafinil. Inhibits the dopamine transporter (DAT) and activates orexin wakefulness pathways. Sustained, motivated alertness without the crash of catecholamine-depleting stimulants.
Next-generation Semax analog — N-acetyl protection plus adamantane C-terminus for dramatically longer half-life and better BBB penetration than NA-Semax alone. Upregulates BDNF and sensitizes hippocampal TrkB receptors for cognitive depth that builds over consistent use.
Every compound, explained
10mL bottle · 5mL fill · 15 doses · 3 sprays × 0.11mL
Anhydrous USP
Caffeine competitively antagonizes adenosine A1 and A2A receptors, preventing the accumulation of drowsiness-inducing adenosine and indirectly increasing dopamine, norepinephrine, and acetylcholine signaling. The molecule is identical to what's in coffee. The delivery is not. Oral caffeine must survive gastric acid, absorb through intestinal walls, transit the portal vein, and survive hepatic first-pass — a 45–90 minute process with highly variable absorption. Nasal absorption delivers working plasma levels in 2–5 minutes. At 8.25mg per dose the effect is meaningful without overwhelming — the fladrafinil ramp carries the sustained load.
CRL-40,941
Fladrafinil (CRL-40,941) is a bis(p-fluoro) ring-substituted derivative of adrafinil, developed by Lafon Laboratories as part of the eugeroic drug class. It is 3–4× more potent than adrafinil with a 15-hour half-life. Its primary mechanism is inhibition of the dopamine transporter (DAT), elevating extracellular dopamine in the nucleus accumbens and prefrontal cortex. Unlike amphetamines which force dopamine release and cause depletion, fladrafinil modulates reuptake — a sustained, non-depleting mechanism. Orexin pathway activation provides a second wakefulness mechanism that operates independently. The result is sustained, motivational alertness: demanding cognitive tasks become tractable for hours without the crash of conventional stimulants.
Peptide
Adamax [Ac-MEHFPGP-AG-Nh2] is the most potent Semax derivative — a synthetic nonapeptide with two structural modifications that separate it from all prior Semax analogs. The N-acetyl group improves blood-brain barrier penetration and metabolic stability. The adamantane group at the C-terminus — a bulky diamondoid lipophilic structure — prevents enzymatic degradation and extends CNS half-life dramatically beyond regular or N-acetyl Semax. This is why users who find Semax completely ineffective often respond to Adamax: the compound persists long enough to produce sustained neurotrophin effects. At 300mcg — Ceretropic's original recommended dose — it upregulates BDNF expression and sensitizes TrkB receptors in the hippocampus. Memory consolidation, verbal fluency, and working memory improve with consistent use. Intranasal delivery provides direct olfactory nerve transport to CNS tissues — more targeted than systemic injection for a hippocampal-targeting peptide.
The onset timeline
Three waves in sequence — not one hit
min
min
What's in the bottle
10mL cobalt glass · 5mL fill · 15 doses · BUD 30 days refrigerated
| Ingredient | Role | Per Dose | Per Bottle | Concentration | Notes |
|---|---|---|---|---|---|
| Caffeine Anhydrous USP ≥99% | Adenosine antagonist | 8.25mg | 123.75mg | 25mg/mL | Water soluble — no cosolvent needed |
| Fladrafinil (CRL-40,941) | DAT inhibitor · eugeroic | 15mg | 225mg | 45.5mg/mL | Poorly water soluble — requires Transcutol HP |
| Adamax [Ac-MEHFPGP-AG-Nh2] | BDNF upregulator · TrkB | 300mcg | 4.5mg | 0.91mg/mL | Peptide — fully water soluble |
| Transcutol HP | Cosolvent — fladrafinil solubilizer | — | 1.0mL | 20% | Required to hold fladrafinil in solution |
| PEG 400 | Co-solvent | — | 0.5mL | 10% | Enhances solubility, viscosity modifier |
| Polysorbate 80 | Surfactant | — | 0.15mL | 3% | Stability, solubilization |
| Citrate buffer pH 5.0 + Sterile Saline USP 0.9% | Buffer + carrier | — | QS to 5mL | pH 5.0 | 0.22µm PES filter mandatory — not nylon or PVDF |
The recommended stack
Eyes Wide Open covers the nasal layer — pair with oral support for the full effect
Eyes Wide Open Nasal
Focus Fire Capsule
Super NAD Injectable
Use it right
| Guideline | Reason | Detail |
|---|---|---|
| Morning use only | Fladrafinil 15hr half-life | 7am dose = 50% blood levels at 10pm. Noon dose = full levels at 3am. Dose no later than midmorning. |
| Once daily maximum | Accumulation risk | Re-dosing within 24 hours compounds blood levels and causes insomnia. One spray per day is the absolute ceiling. |
| Cycle 5 on / 2 off | Tolerance maintenance | Prevents DAT tolerance to fladrafinil. Adamax BDNF effects persist through off days — neuroplasticity gains do not reverse. |
| Add choline support | ACh depletion prevention | DAT inhibitors can accelerate acetylcholine turnover. Alpha-GPC 300mg prevents the headaches common with eugeroics and enhances cognitive effects. |
| Refrigerate 2–8°C | Formulation stability | BUD 30 days. Bring to room temperature before use. Discard if hazy or precipitated. Cobalt UV-blocking glass required. |